Real-world effects of two inhaled corticosteroid/long-acting β₂-agonist combinations in the treatment of asthma

References

• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. National Heart, Lung, and Blood Institute/World Health Organization, Updated 2012. Available from: http:www.ginasthma.org
   Google Scholar
• Tarsin W, Assi KH, Chrystyn H. In-vitro intra- and interinhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J Aerosol Med 2004;17:25–32
   PubMedGoogle Scholar
• Granlund KM, Asking L, Lindblad T, Rollwage U, Steckel H. An in-vitro comparison of budesonide/formoterol and fluticasone/salmeterol in dry powder inhalers. Eur Respir J 2000;16(Suppl. 31):455s
   Google Scholar
• Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lötvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001;14:29–34
   PubMed Web of Science ®Google Scholar
• Zhong N, Lin J, Mehta P, Ngamjanyaporn P, Wu TC, Yunus F. Real-life effectiveness of budesonide/formoterol maintenance and reliever therapy in asthma patients across Asia: SMARTASIA study. BMC Pulm Med 2013;13:22
   Google Scholar
• Dahl R, Chuchalin A, Gor D, Yoxall S, Sharma R. EXCEL: a randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med 2006;100:1152–1162
   PubMed Web of Science ®Google Scholar
• Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martínez-Jimenez NE, Buhl R. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61:725–736
   PubMed Web of Science ®Google Scholar
• Akamatsu T, Shirai T, Kato M, Yasui H, Hashimoto D, Fujisawa T, Tsuchiya T, et al. Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma. Pulm Pharmacol Ther Apr 2014;27:52–56
   Google Scholar
• Akamatsu T, Shirai T, Kato M, Hashimoto D, Yasui H, Inui N, Suda T, et al. Effect of switching from salmeterol/fluticasone to formoterol/budesonide combinations in patients with uncontrolled asthma. Allergol Int 2012;61:323–329
   Google Scholar
• Hozawa S, Terada M, Hozawa M. Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma. Pulm Pharmacol Ther 2011;24:571–576
   PubMedGoogle Scholar
• Hanania NA, King MJ, Braman SS, Saltoun C, Wise RA, Enright P, Falsey AR, et al. Asthma in Elderly workshop participants Asthma in the elderly: current understanding and future research needs – a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol 2011;128:S4–S24
   PubMed Web of Science ®Google Scholar
• Morice AH, Peterson S, Beckman O, Osmanliev D. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. Int J Clin Pract 2007;61:1874–1883
   PubMed Web of Science ®Google Scholar
• Morice AH, Hochmuth L, Ekelund J, Thorén A, Puterman AS. Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma. Pulm Pharmacol Ther 2008;21:32–39
   PubMed Web of Science ®Google Scholar
• Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113:59–65
   PubMed Web of Science ®Google Scholar
• Schatz M, Sorkness CA, Li J, Marcus P, Murray JJ, Nathan RA, Kosinski M. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006;117:549–556
   PubMed Web of Science ®Google Scholar
• Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the asthma control test. J Allergy Clin Immunol 2009;124:719–723
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Koya T, Sakagami T, Kagamu H, Kawakami H, Hara K, Yoshimine F, et al. Efficacy of using the Japanese version of the asthma control test for determining the level of asthma control in clinical settings. Allergol Int 2012;61:609–617
   Google Scholar
• Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99:553–558
   PubMed Web of Science ®Google Scholar
• Juniper E, Bousquet J, Abetz L, Bateman ED, the GOAL Committee. Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. Respir Med 2006;100:616–621
   PubMed Web of Science ®Google Scholar
• The Committee of Pulmonary Physiology, Japanese Respiratory Society. Guidelines for pulmonary function tests. Spirometry, flow-volume curve, diffusing capacity of the lung. Tokyo: The Japanese Respiratory Society (in Japanese), 2004
   Google Scholar
• American College of Chest Physicians. Aerosol consensus statement. Consensus conference on aerosol delivery. Chest 1991;100:1106–1109
   Google Scholar
• Gelfand EW, Kraft M. The importance and features of the distal airways in children and adults. J Allergy Clin Immunol 2009;124(Suppl. 6):S84–S87
   Google Scholar
• Veen JC, Beekman AJ, Bel EH, Sterk PJ. Recurrent exacerbations in sever asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med 2000;161:1902–1906
   PubMed Web of Science ®Google Scholar
• Ueda T, Niimi A, Matsumoto H, Takemura M, Hirai T, Yamaguchi M, Matsuoka H, et al. Role of small airways in asthma: investigation using high-resolution computed tomography. J Allergy Clin Immunol 2006;118:1019–1025
   PubMed Web of Science ®Google Scholar
• Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. β-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med 2002;15:1353–1358
   Google Scholar
• Kume H. Clinical use of β2-adrenergic receptor agonists based on their intrinsic efficacy. Allergol Int 2005;54:89–97
   Google Scholar
• Palmqvist M, Ibsen T, Mellén A, Lötvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999;160:244–249
   Google Scholar
• van der Woude HJ, Boorsma M, Bergqvist PB, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004;17:89–95
   PubMed Web of Science ®Google Scholar
• O’Connor RD, Patrick DL, Parasuraman B, Martin P, Goldman M. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma. J Asthma 2010;47:217–223
   PubMed Web of Science ®Google Scholar
• Adner M, Larsson B, Säfholm J, Naya I, Miller-Larsson A. Budesonide prevents cytokine-induced decrease of the relaxant responses to formoterol and terbutaline, but not to salmeterol, in mouse trachea. J Pharmacol Exp Ther 2010; 333:273–280
   PubMed Web of Science ®Google Scholar
• Tunek A, Sjödin K, Hallström G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997;25:1311–1317
   PubMed Web of Science ®Google Scholar
• Edsbäcker S, Brattsand R. Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data. Ann Allergy Asthma Immunol 2002;88:609–616
   PubMedGoogle Scholar
• Miller-Larsson A, Jansson P, Runström A, Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med 2000;162:1455–1461
   PubMed Web of Science ®Google Scholar